Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity

Journal of Leukocyte Biology

Volumn 90, Issue 4, 2011, Pages 653-660

  Haraguchi, Soichi ^a   Ho, Sarah K ^b   Morrow, Matthew ^a   Goodenow, Maureen M ^b   Sleasman, John W ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Children; HIV 1; Multidrug resistance 1; T cells; Thymus

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; MESSENGER RNA; RHODAMINE 123; RITONAVIR;

ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INFANT; NEWBORN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; THYMOCYTE; THYMUS; VIRAL CLEARANCE; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; P-GLYCOPROTEIN; RNA, MESSENGER; THYMUS GLAND; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80053353735     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0111-009     Document Type: Article

References (52)

1. Ho Tsong Fang, R., Colantonio, A. D., Uittenbogaart, C. (2008) The role of the thymus in HIV infection: a 10 year perspective. AIDS 22, 171-184.
2. Ladi, E., Yin, X., Chtanova, T., Robey, E. A. (2006) Thymic microenvironments for T cell differentiation and selection. Nat. Immunol. 7, 338-343.
3. Kitchen, S. G., Zack, J. A. (1997) CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J. Virol. 71, 6928-6934.
4. Pedroza-Martins, L., Gurney, K. B., Torbett, B. E., Uittenbogaart, C. H. (1998) Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. J. Virol. 72, 9441-9452.
5. Salemi, M., Burkhardt, B. R., Gray, R. R., Ghaffari, G., Sleasman, J. W., Goodenow, M. M. (2007) Phylodynamics of HIV-1 in lymphoid and nonlymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies. PLoS ONE 2, e950.
6. Uittenbogaart, C. H., Anisman, D. J., Jamieson, B. D., Kitchen, S., Schmid, I., Zack, J. A., Hays, E. F. (1996) Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro. AIDS 10, F9-F16.
7. Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan, J. L., Jamieson, B. D., Zack, J. A., Picker, L. J., Koup, R. A. (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396, 690-695.
8. Kourtis, A. P., Ibegbu, C., Nahmias, A. J., Lee, F. K., Clark, W. S., Sawyer, M. K., Nesheim, S. (1996) Early progression of disease in HIVinfected infants with thymus dysfunction. N. Engl. J. Med. 335, 1431-1436.
9. Douek, D. C., Koup, R. A., McFarland, R. D., Sullivan, J. L., Luzuriaga, K. (2000) Effect of HIV on thymic function before and after antiretroviral therapy in children. J. Infect. Dis. 181, 1479-1482.
10. Sleasman, J. W., Nelson, R. P., Goodenow, M. M., Wilfret, D., Hutson, A., Baseler, M., Zickerman, J., Pizzo, P. A., Mueller, B. U. (1999) Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J. Pediatr. 134, 597-606.
11. Yin, L., Rodriguez, C. A., Hou, W., Potter, O., Caplan, M. J., Goodenow, M. M., Sleasman, J. W. (2008) Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD27- CD11a(bright) activated T cells. J. Allergy Clin. Immunol. 122, 166-172.
12. Chavan, S., Bennuri, B., Kharbanda, M., Chandrasekaran, A., Bakshi, S., Pahwa, S. (2001) Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus. J. Infect. Dis. 183, 1445-1454.
13. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181, 946-953.
14. Essajee, S. M., Kim, M., Gonzalez, C., Rigaud, M., Kaul, A., Chandwani, S., Hoover, W., Lawrence, R., Spiegel, H., Pollack, H., Krasinski, K., Borkowsky, W. (1999) Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 13, 2523-2532.
15. Rodriguez, C. A., Koch, S., Goodenow, M. M., Sleasman, J. W. (2008) Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. Immunol. Res. 40, 271-286.
16. Kitchen, S. G., Killian, S., Giorgi, J. V., Zack, J. A. (2000) Functional reconstitution of thymopoiesis after human immunodeficiency virus infection. J. Virol. 74, 2943-2948.
17. Pettoello-Mantovani, M., Kollmann, T. R., Raker, C., Kim, A., Yurasov, S., Tudor, R., Wiltshire, H., Goldstein, H. (1997) Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues. Antimicrob. Agents Chemother. 41, 1880-1887.
18. Stoddart, C. A., Joshi, P., Sloan, B., Bare, J. C., Smith, P. C., Allaway, G. P., Wild, C. T., Martin, D. E. (2007) Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE 2, e1251.
19. Stoddart, C. A., Liegler, T. J., Mammano, F., Linquist-Stepps, V. D., Hayden, M. S., Deeks, S. G., Grant, R. M., Clavel, F., McCune, J. M. (2001) Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat. Med. 7, 712-718.
20. Delph, Y. (2002) P-glycoprotein and HIV. GMHC Treat. Issues 16, 6-10.
21. Gutmann, H., Fricker, G., Drewe, J., Toeroek, M., Miller, D. S. (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 56, 383-389.
22. Huisman, M. T., Smit, J. W., Schinkel, A. H. (2000) Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14, 237-242.
23. Lee, C. G., Ramachandra, M., Jeang, K. T., Martin, M. A., Pastan, I., Gottesman, M. M. (2000) Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14, 516-522.
24. Lucia, M. B., Rutella, S., Leone, G., Vella, S., Cauda, R. (2001) HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J. Acquir. Immune Defic. Syndr. 27, 321-330.
25. Sankatsing, S. U., Beijnen, J. H., Schinkel, A. H., Lange, J. M., Prins, J. M. (2004) P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob. Agents Chemother. 48, 1073-1081.
26. Janneh, O., Jones, E., Chandler, B., Owen, A., Khoo, S. H. (2007) Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 60, 987-993.
27. Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., Back, D. J. (2001) P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15, 1353-1358.
28. Chaudhary, P. M., Mechetner, E. B., Roninson, I. B. (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80, 2735-2739.
29. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Huber, H., Andreeff, M. (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80, 2729-2734.
30. Klimecki, W. T., Futscher, B. W., Grogan, T. M., Dalton, W. S. (1994) P-glycoprotein expression and function in circulating blood cells fromnormal volunteers. Blood 83, 2451-2458.
31. Ludescher, C., Pall, G., Irschick, E. U., Gastl, G. (1998) Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br. J. Haematol.101, 722-727.
32. Pilarski, L. M., Paine, D., McElhaney, J. E., Cass, C. E., Belch, A. R.(1995) Multidrug transporter P-glycoprotein 170 as a differentiationantigen on normal human lymphocytes and thymocytes: modulationwith differentiation stage and during aging. Am. J. Hematol. 49, 323-335.
33. Chong, A. S., Markham, P. N., Gebel, H. M., Bines, S. D., Coon, J. S. (1993) Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol. Immunother. 36, 133-139.
34. + T cells: a role in cytotoxic effector function. J. Clin. Immunol. 12, 451-458.
35. Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., Khoo, S. H. (2004) Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J. Virol. 78, 12022-12029.
36. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., Dey, S. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37, 3594-3601.
37. Ho, S. K., Coman, R. M., Bunger, J. C., Rose, S. L., O'Brien, P., Munoz, I., Dunn, B. M., Sleasman, J. W., Goodenow, M. M. (2008) Drugassociatedchanges in amino acid residues in Gag p2, p7NC, and p6Gag/p6Pol in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 378, 272-281.
38. Toffoli, G., Simone, F., Corona, G., Raschack, M., Cappelletto, B., Gigante, M., Boiocchi, M. (1995) Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol. 50,1245-1255.
39. Johnstone, R. W., Ruefli, A. A., Smyth, M. J. (2000) Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci. 25, 1-6.
40. Loo, T. W., Clarke, D. M. (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206, 173-185.
41. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. (1987) Cellular localization of the multidrug-resistancegene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738.
42. Van der Valk, P., van Kalken, C. K., Ketelaars, H., Broxterman, H. J., Scheffer, G., Kuiper, C. M., Tsuruo, T., Lankelma, J., Meijer, C. J. L. M., Pinedo, H. M., Scheper, R. J. (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann. Oncol. 1, 56-64.
43. Res, P., Blom, B., Hori, T., Weijer, K., Spits, H. (1997) Downregulation of CD1 marks acquisition of functional maturation of human thymocytesand defines a control point in late stages of human T cell development. J. Exp. Med. 185, 141-151.
44. Liu, Y., Hu, M. (2000) P-glycoprotein and bioavailability-implication of polymorphism. Clin. Chem. Lab. Med. 38, 877-881.
45. Marzolini, C., Paus, E., Buclin, T., Kim, R. B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33.
46. Zaitseva, M. B., Lee, S., Rabin, R. L., Tiffany, H. L., Farber, J. M., Peden, K. W., Murphy, P. M., Golding, H. (1998) CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J. Immunol. 161, 3103-3113.
47. Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., Chiba, P. (2009) P-Glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir. Ther. 14, 965-974.
48. Drewe, J., Gutmann, H., Fricker, G., Torok, M., Beglinger, C., Huwyler, J. (1999) HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57, 1147-1152.
49. Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., Gibbons, S. E., Breckenridge, A. M., Back, D. J. (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11, F29-F33.
50. Berkowitz, R. D., Beckerman, K. P., Schall, T. J., McCune, J. M. (1998) CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J. Immunol. 161, 3702-3710.
51. Brooks, D. G., Kitchen, S. G., Kitchen, C. M., Scripture-Adams, D. D., Zack, J. A. (2001) Generation of HIV latency during thymopoiesis. Nat. Med. 7, 459-464.
52. Aldrovandi, G. M., Feuer, G., Gao, L., Jamieson, B., Kristeva, M., Chen, I. S., Zack, J. A. (1993) The SCID-hu mouse as a model for HIV-1 infection. Nature 363, 732-736.